BD, the Franklin Lakes-based global medical technology company, has acquired MedKeeper, a provider of modern, cloud-based pharmacy management applications.
MedKeeper complements BD’s existing presence in the pharmacy – where the company has pioneered solutions in compounding, logistics workflow, controlled substance management and inventory optimization.
MedKeeper’s platform will become part of the BD’s existing portfolio of connected medication management capabilities. By combining MedKeeper’s platform with BD’s broad technology expertise, the companies will work to optimize the preparation of compounded medications – a critical need in the pharmacy today.
“Preparing the right dose for patients requires a combination of factors – including personnel, training, and compliance. Pharmacy leaders require IV workflow management technology that is personalized to their needs and works within their environment,” said Mike Garrison, worldwide president of medication management solutions at BD. “Adding MedKeeper to our portfolio will enable us to offer our customers easy to use, customizable solutions that make meaningful and incremental progress in IV workflow management.”
“Demands in today’s pharmacy environment, such as COVID-impacted labor shortages and changing regulatory requirements, have further exacerbated the need for customizable pharmacy software solutions to support flexible, directed workflow, inventory tracking and reporting needs in sterile and non-sterile compounding,” said Garrison. “Manual, time-consuming procedures that might once have been ‘good enough’ now can be replaced and augmented by software that enables pharmacists to provide a higher standard of care.”
BD and MedKeeper will work to provide customers with flexibility and capabilities in meeting industry standards for preparing compounded medications, incorporating the latest regulatory guidance. Together, the companies are dedicated to ensuring that every customer has a workflow solution that best supports their environment and delivers efficiencies to their frontline clinicians.
The transaction is expected to be immaterial to BD’s fiscal 2022 financial results.
To access more business news, visit NJB News Now.Related Articles: